Clinical Trials Logo

Myelomeningocele clinical trials

View clinical trials related to Myelomeningocele.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04484441 Active, not recruiting - Spina Bifida Clinical Trials

Maternal-fetal Immune Responses to Fetal Surgery

Start date: March 24, 2022
Phase:
Study type: Observational

Performing surgery in utero on fetuses with certain birth defects has led to significant improvements in outcomes after birth; however, many of these infants are born preterm which can decrease the effectiveness of these procedures. The investigators aim to understand the effects of surgery on the maternal and fetal immune system and whether immune activation may be causing some of these infants to be born prematurely.

NCT ID: NCT04251806 Active, not recruiting - Clinical trials for Sleep-disordered Breathing

Sleep-disordered Breathing in Infants With Myelomeningocele

Start date: July 21, 2020
Phase:
Study type: Observational

This study aims to determine whether the risk for sleep-disordered breathing in infants with myelomeningocele (a severe form of spina bifida) differs among those who underwent fetal vs. postnatal surgery, and to examine the link between sleep-disordered breathing and neurodevelopment.

NCT ID: NCT04243889 Active, not recruiting - Spina Bifida Clinical Trials

Fetoscopic NEOX Cord 1K® Spina Bifida Repair

Start date: August 28, 2020
Phase: N/A
Study type: Interventional

To fetoscopically use cryopreserved human umbilical cord allografts, named NEOX Cord 1K®, as a spinal cord cover of spina bifida defects. This procedure will be performed to create a watertight seal covering over the spinal cord in order to decrease the incidence rates of postnatal morbidities. For larger skin defects, NEOX Cord 1K® may be used as a skin cover.

NCT ID: NCT03936322 Active, not recruiting - Spina Bifida Clinical Trials

Minimally Invasive Fetoscopic Regenerative Repair of Spina Bifida - A Pilot Study

Start date: May 7, 2019
Phase: N/A
Study type: Interventional

Researchers are studying a new minimally invasive technique (fetoscopic repair) for repair of spina bifida (MMC) during the second trimester of pregnancy. Researchers are trying to determine if this less invasive surgical approach will have less risk to the mother and at the same time adequate closure of the fetal spina bifida defect.

NCT ID: NCT03090633 Active, not recruiting - Spina Bifida Clinical Trials

Fetoscopic Repair of Isolated Fetal Spina Bifida

Start date: May 11, 2017
Phase: N/A
Study type: Interventional

The purpose of this investigation is to evaluate maternal and fetal outcomes following fetoscopic repair of fetal spina bifida at the Johns Hopkins Hospital. The hypothesis of this study is that fetoscopic spina bifida repair is feasible and has the same effectiveness as open repair of fetal spina bifida, but with the benefit of significantly lower maternal and fetal complication rates. The fetal benefit of the procedure will be the prenatal repair of spina bifida. The maternal benefit of fetoscopic spina bifida repair will be the avoidance of a large uterine incision. This type of incision increases the risk of uterine rupture and requires that all future deliveries are by cesarean section. The use of the minimally invasive fetoscopic surgical technique may also lower the risk of preterm premature rupture of membranes and preterm birth compared to open fetal surgery. Finally, successful fetoscopic spina bifida repair also makes vaginal delivery possible.

NCT ID: NCT00175123 Active, not recruiting - Myelomeningocele Clinical Trials

Effect of Botulinum Toxin in Neurogenic Bladders in Children With Myelomeningocele

Start date: May 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study is to examine how injection of botulinum toxin in the bladder affects bladder function. The trial is carried out in children born with malformation of the spinal cord and subsequent overactive bladders. The purpose of treating the bladder (with different drugs) is to prevent damage to the kidneys and renal function. The aim of this study is to compare a conventionally used drug (oxybutynin) with botulinum toxin. The hypothesis of the study is that botulinum toxin is equal to oxybutynin in the treatment of overactive bladder.